Scott Lyman
Chief Executive Officer Belhaven Biopharma
Seminars
Wednesday 20th May 2026
Designing Device & Contract Manufacturing Considerations to Enable Scalable and Commercially Viable Intranasal Products
11:00 am
- Understand the critical difference between producing batches for early studies versus large-scale commercial production.
- Learn how to assess partner capabilities, capital readiness and long-term vision to ensure they can support commercialization, not just development
- Explore strategies to align device design, manufacturing investment and regulatory timelines when capital and resources are constrained
